A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus
Genzyme, a Sanofi Company
Information provided by (Responsible Party)
First received: August 3, 2006
Last updated: February 10, 2014
Last Verified: February 2014
History of Changes
The purpose of this study is to determine the safety and activity of AMD11070 in HIV-infected patients carrying X4-tropic virus.
X4 Tropic Virus
Drug : AMD11070
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Multicenter, Dose-finding Safety and Activity Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus.|
Further study details as provided by Sanofi:
Primary Outcome Measures
- safety and antiviral activity of AMD11070 administered in HIV-infected patients who harbor-X4-tropic virus. [ Time Frame: 10 days ]
- the proportion of patients per cohort who have a ≥1 log10 rlu reduction in X4-tropic virus and to describe changes from baseline to Day 10 in log10 rlu corresponding to X4-tropic virus. [ Time Frame: 10 days ]
- the relationship between standard pharmacokinetic (PK) measures, viral response, and a shift in T-cell receptor tropism. [ Time Frame: 10 days ]
- the relationship of coreceptor tropism phenotype to CD4+ count, viral load, and drug resistance in the screening patient population. [ Time Frame: 10 days ]
- the virologic activity of AMD11070 at day 10 of study treatment by analyzing the proportion of patients with Plasma HIV-1 RNA levels <400 and <50 copies/ml and the proportion with a >1 log10 decline in plasma HIV from baseline. [ Time Frame: 10 days ]
- changes in CD4+ cell counts and percentages on and off AMD11070. [ Time Frame: 10 days ]
- change from baseline in CD34+ cells [ Time Frame: 10 days ]
|Study Start Date:||October 2005|
|Study Completion Date:||April 2010|
|Primary Completion Date:||August 2006 (Final data collection date for primary outcome measure)|
AMD11070 is a new chemical entity that inhibits HIV-1 entry by binding specifically and
reversibly to CXCR4, a coreceptor required by T-tropic virus for membrane fusion and entry
into cells. The purpose of this study is to evaluate the safety and relative antiretroviral
activity of AMD11070 in HIV-infected individuals who have demonstrated X4 -tropic virus in
their plasma. With the ongoing development of other fusion and entry inhibitors and the need
for alternative treatment options in patients (especially those with multidrug resistant
virus), the demonstration of activity and safety of AMD11070 represents a potentially
important advance in antiretroviral therapeutics. This will be the first study that
determines the therapeutic potential of anti-CXCR4 compounds in HIV-infected patients.
Note: Study was previously suspended due to non-clinical reports of hepatotoxicity and histologic findings. Study has been completed.
|Ages Eligible for Study:||18 Years and older|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- HIV-1 infection, as documented by any licensed ELISA test kit (confirmed by Western Blot), HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, cDNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test.
- Both antiretroviral treatment-naïve and -experienced patients. Treatment-experienced patients currently on antiretroviral therapy are required to have a washout period of at least 14 days prior to study entry.
- Presence of X4 tropic virus as determined by a luciferase activity of ≥2000 rlu on the HIV-1 coreceptor tropism assay from a sample collected no more than 56 days prior to study baseline.
- Peripheral blood CD4+ cell count ≤200 cells/mm^3.
- Plasma HIV-1 RNA ≥5000 copies/ml by any standard assay.
- Laboratory values prior to study entry: A. Absolute neutrophil count (ANC) ≥750/mm^3. B. WBC ≥1500/mm^3. C. Hemoglobin ≥10g/dL. D. Platelet count ≥80,000/mm^3. E. Creatinine ≤ 1.2 x ULN. F. AST (SGOT), ALT (SGPT), and alkaline phosphatase ≤ 1.5 x ULN. G. Total bilirubin ≤ 1.2 x ULN. Note: Except for patients who are on atazanavir or indinavir during screening. For these patients, total bilirubin ≤ 4.0 x ULN will be permitted. H. Serum lipase within normal limits. I. PT and PTT ≤ 1.2 x ULN. J. Calcium and magnesium within normal limits.
- Female patients of reproductive potential must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/ml performed within 24 hours before study entry and initiation of the protocol-specified medication..
- All patients must agree not to participate in the conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization).
- Willingness of female patients to discontinue hormonal contraception 1 week prior to study entry. Note: Female patients who discontinue hormonal contraception prior to study entry may resume hormonal contraception after study day 11.
- Karnofsky performance score ≥90 at screening.
- Ability and willingness of patient or legal guardian/representative to give written informed consent.
- Patients with a known sensitivity to AMD11070 and its excipients (cellulose, croscarmellose, sodium stearyl fumarate, silicone dioxide, calcium phosphate dihydrate,sodium lauryl sulfate).
- Pregnancy or breast-feeding.
- Any antiretroviral treatment within 14 days prior to study entry.
- Any immunizations within 30 days prior to study entry.
- Treatment with radiation therapy or cytotoxic chemotherapy agents or immuno-modulating agents within 30 days prior to study entry.
- Use of contraindicated prescription medications, herbal supplements, or aspirin within seven days prior to study entry.
- Use of any CYP-3A4 inhibitors or inducers, and P-gp inducers and inhibitors. Use of CYP-450 substrates are allowed in the protocol with the exception of CYP-2D6 and CYP-2C8 substrates.
- Use of any investigational drug (i.e. drugs not approved for any indication) within 30 days prior to study entry.
- Evidence of active infection or acute illness of any kind within 14 days prior to study entry,including HIV-associated opportunistic infection.
- Chronic diarrhea defined as >3 stools/day for more than 4 weeks prior to study entry.
- Documented history of cardiac conduction abnormalities, cardiac arrhythmias, or cardiomyopathy, any repolarization delay (QTc >500msec) or a history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalemia).
- Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
- Any other medical or psychological condition that might, in the opinion of the site
Contacts and LocationsChoosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00361101
Locations Show More
|United States, Florida|
|Orlando, Florida, United States, 32803|
|London, United Kingdom, SW10 9TH|
Sponsors and CollaboratorsGenzyme, a Sanofi Company
|Study Director:||Medical Monitor||Genzyme, a Sanofi Company|
|Responsible Party:||Medical Monitor, Genzyme|
|ClinicalTrials.gov Identifier:||NCT00361101 History of Changes|
|Other Study ID Numbers:||AMD11070-1001|
|Study First Received:||August 3, 2006|
|Last Updated:||February 10, 2014|
Keywords provided by Sanofi:HIV
X4 tropic virus
Additional relevant MeSH terms:
ClinicalTrials.gov processed this data on October 20, 2017
This information is provided by ClinicalTrials.gov.